Name | Title | Contact Details |
---|
Cooley Dickinson Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Cooley Dickinson Hospital is based in Northampton, MA. You can find more information on Cooley Dickinson Hospital at www.cooley-dickinson.org
Advanced Excimer Laser-Based Vascular and Dermatological Therapies We are a medical device company leveraging our advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases. We believe our products enhance patients` quality of life by restoring blood-flow in arteries and clearing chronic skin conditions. We currently manufacture and market two lines of products: DABRA Catheter and Laser is cleared by the U.S. FDA as a tool for the minimally invasive endovascular treatment of vascular blockages resulting from lower extremity vascular disease, including peripheral artery disease (PAD) and critical limb ischemia (CLI). Pharos Excimer Laser is FDA cleared as a tool used in the treatment of inflammatory skin conditions, including psoriasis, atopic dermatitis, and leukoderma.
Hammer Medical is a Des Moines, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.
Biography Identity is a Bellingham, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.